Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients.
Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients.
复制标题
粘蛋白-1及其与卵巢癌患者的等级，阶段和生存关系的关系。
DOI：
10.1186/1471-2407-12-600
复制
发表时间：
2012-12-15
期刊：
影响因子：
3.8
通讯作者：
Jeschke U
中科院分区：
文献类型：
--
作者：
Engelstaedter V;Heublein S;Schumacher AL;Lenhard M;Engelstaedter H;Andergassen U;Guenthner-Biller M;Kuhn C;Rack B;Kupka M;Mayr D;Jeschke U
已知粘蛋白-1被各种人类癌过度表达，并被释放到循环中，在循环中可以通过特异性抗粘蛋白-1抗体（例如肿瘤标志物测定CA 15-3和CA 27.29）在患者血清中检测到粘蛋白-1。Mucin-1在卵巢癌中表达的预后价值仍不确定。本研究的一个目的是比较一组良性或恶性卵巢肿瘤患者（CA 15-3和CA 27.29检测）中粘蛋白-1的浓度。本研究的另一个目的是通过免疫组织化学方法评估不同队列卵巢癌患者中粘蛋白-1的表达与分级、分期和生存率的关系。诊断为卵巢肿瘤并接受治疗的患者被纳入研究。患者特征、组织学（包括组织学亚型）、肿瘤分期、分级和随访数据可从患者记录中获得。血清粘蛋白-1浓度用检测CA 15-3和CA 27.29的ELISA技术测定，粘蛋白-1组织表达用免疫组织化学使用抗粘蛋白-1抗体VU 4 H5和VU 3C 6测定。采用SPSS18.0进行统计学分析。获得118名卵巢肿瘤患者的血清样品以测定粘蛋白-1水平。恶性肿瘤患者的CA 15-3和CA 27.29浓度中位数显著高于良性肿瘤患者（p< 0.001）。154例卵巢癌患者的石蜡包埋组织可用于测定Mucin-1表达。大多数患者在初步诊断时表现为晚期疾病。中位随访时间为11.39年。VU 4 H5的免疫组化结果显示在肿瘤分级、FIGO分期和总生存期方面存在显著差异。Mucin-1表达阴性患者的平均总生存期为9.33年，而Mucin-1表达阳性患者的平均总生存期为6.27年。这项研究发现，与患有良性卵巢疾病的妇女相比，卵巢癌患者的血清粘蛋白-1浓度显著升高。然而，需要注意的是，癌患者中的粘蛋白-1浓度显示出相当高的变异性。免疫组化结果表明，Mucin-1在卵巢癌中具有预后相关性，当评估VU 4 H5抗体的表达时。
Mucin-1 is known to be over-expressed by various human carcinomas and is shed into the circulation where it can be detected in patient’s serum by specific anti-Mucin-1 antibodies, such as the tumour marker assays CA 15–3 and CA 27.29. The prognostic value of Mucin-1 expression in ovarian carcinoma remains uncertain. One aim of this study was to compare the concentrations of Mucin-1 in a cohort of patients with either benign or malignant ovarian tumours detected by CA 15–3 and CA 27.29. Another aim of this study was to evaluate Mucin-1 expression by immunohistochemistry in a different cohort of ovarian carcinoma patients with respect to grade, stage and survival. Patients diagnosed with and treated for ovarian tumours were included in the study. Patient characteristics, histology including histological subtype, tumour stage, grading and follow-up data were available from patient records. Serum Mucin-1 concentrations were measured with ELISA technology detecting CA 15–3 and CA 27.29, Mucin-1 tissue expression was determined by immunohistochemistry using the VU4H5 and VU3C6 anti-Mucin-1 antibodies. Statistical analysis was performed by using SPSS 18.0. Serum samples of 118 patients with ovarian tumours were obtained to determine levels of Mucin-1. Median CA 15–3 and CA 27.29 concentrations were significantly higher in patients with malignant disease (p< 0.001) than in patients with benign disease. Paraffin-embedded tissue of 154 patients with ovarian carcinoma was available to determine Mucin-1 expression. The majority of patients presented with advanced stage disease at primary diagnosis. Median follow-up time was 11.39 years. Immunohistochemistry results for VU4H5 showed significant differences with respect to tumour grade, FIGO stage and overall survival. Patients with negative expression had a mean overall survival of 9.33 years compared to 6.27 years for patients with positive Mucin-1 expression. This study found significantly elevated Mucin-1 serum concentrations in ovarian carcinoma patients as compared to those women suffering from benign ovarian diseases. However, it needs to be noted that Mucin-1 concentrations in carcinoma patients showed a rather high variability. Results from immunohistochemistry indicate that Mucin-1 has a prognostic relevance in ovarian carcinomas when evaluating the expression by VU4H5 antibody.
登录
查看更多内容
影响因子：
2
作者：
Duffy, MJ;Shering, S;O'Higgins, N
通讯作者：
O'Higgins, N
影响因子：
50.5
作者：
Berek, JS;Tropé, C;Vergote, I
通讯作者：
Vergote, I
影响因子：
--
作者：
Price, MR;Rye, PD;Hilgers, J
通讯作者：
Hilgers, J
影响因子：
5.8
作者：
Budiu, Raluca A.;Mantia-Smaldone, Gina;Vlad, Anda M.
通讯作者：
Vlad, Anda M.
影响因子：
6.4
作者：
Van Elssen, Catharina H. M. J.;Frings, Peter W. H.;Bos, Gerard M. J.
通讯作者：
Bos, Gerard M. J.